Level 1 — Absolute Beginner

Some people stop breathing for a few seconds when they sleep. It happens many times each night. This problem is called sleep apnea. People with it often snore, and they feel tired all day.

Many people with sleep apnea are also very heavy. Doctors often give them a machine with a mask. They wear the mask in bed. It pushes air into the nose and mouth. Many people do not like it.

Now there is news about a pill. Its name is Foundayo. People take it once a day. It helps them lose weight.

A big study tested the pill for one year. People who took it stopped breathing much less often at night. In one group, the number fell by about 44 percent. The company now wants the United States government to say yes to the pill for sleep apnea.

breathing

Taking air in and out of your body.

snore

To make a loud noise when you sleep.

tired

Feeling that you need to rest or sleep.

heavy

Weighing a lot.

mask

A cover that you wear over your face.

pill

A small, hard piece of medicine that you swallow.

weight

How heavy a person or thing is.

study

A careful test to learn if something is true.

Level 2 — Elementary

A daily weight-loss pill can make obstructive sleep apnea much less severe, according to results announced on Monday, 9 November, by the American drug company Eli Lilly. The pill is called Foundayo, and its scientific name is orforglipron. The findings were presented at a large meeting of heart doctors and published in the medical journal JAMA.

In sleep apnea, the airway closes again and again during sleep, so breathing stops for short moments. The condition is common in people with obesity. It leaves patients exhausted, and it raises the risk of heart disease. The usual treatment is a PAP machine, which blows air through a mask all night.

Lilly ran two trials that lasted 52 weeks. All the adults in them had moderate or severe sleep apnea and were overweight. Among people who did not use a PAP machine, breathing interruptions fell by 43.8 percent with Foundayo. With a placebo, a pill with no medicine in it, they fell by only 6.3 percent. Among PAP users, the fall was 27.5 percent.

Patients also lost weight, about 28 pounds on average. The most common side effects were stomach problems. Lilly says it will ask the Food and Drug Administration to approve the pill for sleep apnea before the end of 2026.

severe

Very bad or serious.

journal

A magazine that publishes scientific research.

airway

The passage that air moves through when you breathe.

obesity

The medical condition of having too much body fat.

exhausted

Extremely tired.

trials

Tests of a medicine on groups of people.

placebo

A pill with no medicine in it, used for comparison in tests.

side effects

Unwanted results of taking a medicine.

Level 3 — Intermediate

For years the standard answer to obstructive sleep apnea has been a bedside machine and a mask. A second pharmaceutical option moved closer this week. On Monday, 9 November, Eli Lilly reported that its once-daily pill Foundayo, known generically as orforglipron, significantly reduced the severity of the condition in two late-stage trials. The results were presented at the American Heart Association's Scientific Sessions and published simultaneously in JAMA.

The ATTAIN-OSA program enrolled adults with moderate-to-severe apnea who were also obese or overweight, and followed them for 52 weeks. One trial studied people who were not using positive airway pressure, or PAP, therapy, and the other studied people who were. The main measure was the apnea-hypopnea index, which counts how often breathing stops or becomes shallow each hour. In the non-PAP trial the index fell 43.8 percent on Foundayo against 6.3 percent on placebo. In the PAP trial the figures were 27.5 percent and 3.0 percent. By Lilly's account, up to 32 percent of participants reached remission or only mild disease.

Foundayo belongs to the GLP-1 family of medicines, which reduce appetite. Participants lost a little more than 11 percent of their body weight, and less fat around the throat generally means a more open airway. A related measure, the amount of oxygen lost during each night, also improved sharply, falling 55.9 percent in non-PAP users.

There are caveats. Lilly's headline figures assume that every participant stayed on treatment for the full year. Serious adverse events were more frequent on the drug than on placebo, at 8.8 percent against 4.9 percent in one trial. And although six of seven secondary goals were met, a combined measure of how impaired patients felt was not clearly better. One commentator told the cardiology site TCTMD that "the jury is still out" on symptoms. Lilly plans to file with the Food and Drug Administration by the end of the year.

pharmaceutical

Connected with the making of medicines.

generically

By its scientific name, not its brand name.

simultaneously

At exactly the same time.

enrolled

Officially included people in a study or course.

remission

A period when the signs of a disease disappear.

appetite

The feeling of wanting to eat.

caveats

Warnings or limits that you should keep in mind.

adverse

Harmful or unwanted.

Level 4 — Advanced

The pharmacology of obesity has been colonizing adjacent diseases for several years, and obstructive sleep apnea is the latest territory to yield. Eli Lilly's injectable tirzepatide already carries an apnea indication in the United States. On 9 November the company presented evidence that an oral successor can do something similar. In the twin ATTAIN-OSA trials, reported at the American Heart Association's Scientific Sessions and in JAMA, the once-daily tablet Foundayo, or orforglipron, cut the apnea-hypopnea index by 43.8 percent over 52 weeks in patients not using positive airway pressure, against 6.3 percent with placebo. Among those already on PAP, the reduction was 27.5 percent against 3.0 percent.

The mechanism is almost certainly indirect. Orforglipron is a small-molecule GLP-1 receptor agonist that suppresses appetite. Participants shed roughly 11 percent of their body weight, about 28 pounds, and the upper airway, relieved of surrounding fat, collapses less readily. Hypoxic burden, a measure of cumulative oxygen deprivation that some researchers consider more prognostic than the raw event count, fell by 55.9 percent in the non-PAP cohort and 45.8 percent in the PAP cohort. Lilly says as many as 32 percent of participants ended the year in remission or with only mild disease.

The appeal of a tablet is obvious to anyone who has abandoned a PAP mask, as a substantial share of patients eventually do. Adherence, not efficacy, has always been the weak point of mechanical therapy. A pill also sidesteps the cold-chain logistics and needle aversion that limit injectables. If the Food and Drug Administration agrees, and Lilly intends to submit before the year is out, apnea could become one more reason for physicians to prescribe a class of drugs whose cost already strains insurers.

Enthusiasm should be tempered by the fine print. The headline numbers derive from an efficacy estimand that models every randomized participant as fully adherent for a year, a flattering assumption. Serious adverse events ran higher on the drug, at 8.8 percent against 4.9 percent in one trial, and gastrointestinal complaints were common. Most tellingly, a pooled patient-reported measure of sleep-related impairment did not reach significance, even as six of seven key secondary endpoints did. Fewer interrupted breaths on a sleep-laboratory trace is a surrogate. Whether patients feel more awake, and whether their hearts fare better over a decade, are separate questions that these trials were not built to settle.

pharmacology

The science of how medicines act on the body.

indication

An approved medical use for a drug.

mechanism

The way in which something works or produces an effect.

cohort

A group of people studied together in research.

prognostic

Useful for predicting how a disease will develop.

adherence